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Abstract
Introduction In adjuvant treatment for breast cancer there is no
tool available with which to measure the efficacy of the therapy.
In contrast, in neoadjuvant therapy reduction in tumour size is
used as an indicator of the sensitivity of tumour cells to the
agents applied. If circulating epithelial (tumour) cells can be
shown to react to therapy in the same way as the primary
tumour, then this response may be exploited to monitor the
effect of therapy in the adjuvant setting.
Method We used MAINTRAC®  analysis to monitor the
reduction in circulating epithelial cells during the first three to
four cycles of neoadjuvant therapy in 30 breast cancer patients.
Results MAINTRAC®  analysis revealed a patient-specific
response. Comparison of this response with the decline in size
of the primary tumour showed that the reduction in number of
circulating epithelial cells accurately predicted final tumour
reduction at surgery if the entire neoadjuvant regimen consisted
of chemotherapy. However, the response of the circulating
tumour cells was unable to predict the response to additional
antibody therapy.
Conclusion The response of circulating epithelial cells faithfully
reflects the response of the whole tumour to adjuvant therapy,
indicating that these cells may be considered part of the tumour
and can be used for therapy monitoring.
Introduction
One of the major obstacles to improving breast cancer treat-
ment is the lack of a sensitive and specific assay with which to
evaluate the effect of therapy in the adjuvant setting and in
metastatic disease. It has been shown that cells can be shed
from the tumour at all stages of disease and that these cells
may remain in the patient's circulation for lengthy periods after
initial treatment of the primary tumour [1,2], but in a proportion
of patients these can eventually develop into metastases.
Numbers of such cells vary depending on the method and
sample, from very few if bone marrow mononuclear cells are
analyzed (median 2 per 2 × 106 in breast cancer patients) [3]
to between 5 and 20,000 cells per 7.5 ml blood sample (cor-
responding to 6 to 25,000 cells per 2 × 106 mononuclear
blood cells) [4] in metastatic breast cancer. Using magnetic
bead enrichment and microfluorimetry [5] in lung cancer
patients after surgery we had identified numbers of cells [6]
similar to those reported by Cristofanilli and coworkers [4].
Recently, we improved this method to avoid cell loss resulting
from enrichment procedures and centrifugation, and we were
able to detect even higher numbers of epithelial cells in
patients with malignant epithelial tumours (between 50/ml and
300,000/ml in more than 90% of patients) [7]. The question
then arises regarding whether these epithelial cells, which are
detectable in such high numbers, are indeed tumour cells. Pre-
operative chemotherapy in breast cancer patients [8,9] pro-
vides a model in which to address this question. In these
patients the initial size of the tumour, as analyzed by magnetic
resonance imaging before therapy, can be compared with the
size determined by pathological analysis of the remaining
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tumour tissue after therapy at surgery [10]. This reduction in
size can be correlated to the reduction in numbers of blood
epithelial cells.
Materials and methods
In order to measure the reduction in circulating epithelial cells
induced by neoadjuvant chemotherapy, we monitored epithe-
lial cells before each therapy cycle in 30 patients with breast
cancer treated with two different neoadjuvant chemotherapy
schedules [11,12]. Only the first three (dose intensified) epiru-
bicin or four epirubicin/cyclophosphamide cycles of the regi-
men were considered in the analysis because measurement of
the numbers of cells during the following cycles was con-
founded by release of cells from disintegrating tumour tissue
(Camara O and coworkers, unpublished data).
Once informed consent had been obtained from all partici-
pants, as required for ethics committee approval, peripheral
blood anticoagulated with EDTA was drawn before the start of
therapy and before each of the following therapy cycles. As a
control, blood from 25 patients with nonepithelial haematolog-
ical malignancies in different stages of disease (seven with
chronic myelogenous leukaemia (five in clinical remission and
two who had relapsed), five with acute lymphocytic leukemia
(two in clinical remission), five with acute myelogenous leuke-
mia (two in clinical remission after allogeneic stem cell trans-
plantation) and eight patients with plasmocytoma (five in
clinical remission after autologous stem cell transplantation
and three who had relapsed)) was also analyzed for circulating
cell staining with the antiepithelial antibody. First, red blood
cells were lysed using ammonium chloride, which was fol-
lowed by a single centrifugation step. Then, the pellet of white
cells was collected (in accordance with a previously described
approach [7]) and incubated with FITC-conjugated mouse
anti-human epithelial antibody (HEA; Miltenyi Bergisch Glad-
bach, Germany), and live cells in suspension were applied to
a poly-L-lysine treated slide, which was analyzed using a Laser
Scanning Cytometer® (Compucyte Corporation, Cambridge,
MA, USA) [11]. This method, termed MAINTRAC® analysis,
enables relocation of cells for visual examination and quantifi-
cation, and for taking fluoromicrographs. Typical cells (green
fluorescence, exclusively located at the surface, indicative for
viability, often forming caps) are shown in Fig. 1; note that the
right-most cell is counter-stained for the oestrogen receptor.
Figure 1
Fluorimetric analysis, relocalization and fluoromicrograph of individual circulating tumour cells Fluorimetric analysis, relocalization and fluoromicrograph of individual circulating tumour cells. Shown are the procedure for quantification and visual 
control (1 hour for cell preparation and analysis) and three typical viable circulating tumour cells (green fluorescing cap). One cell is also stained for 
oestrogen receptor (orange fluorescence).Available online http://breast-cancer-research.com/content/7/6/R975
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Results
In previous experiments [7] we performed combination stain-
ing with anti-CD45-PE and restaining with cytokeratin, and
found that CD45+ blood cells could easily be discriminated
from epithelial cells, and that all cells staining with anti-EpCAM
(epithelial cell specific adhesion molecule) also stained with
cytokeratin. Nonspecific staining with anti-EpCAM can occur
when one is using fixed cells and intracellular staining, but this
was not a problem when live cells were analyzed, which were
defined as cells exhibiting exclusive surface staining. In the
previous study [7] no live epithelial antigen positive cells were
detected in 97% of healthy donors aged between 17 and 75
years.
In none of the patients with haematological malignancies,
whether full blown, in complete remission with regenerating
haematopoiesis, or in relapse, could we detect cells staining
with the HEA antibody. In breast cancer patients assigned to
neoadjuvant treatment, live epithelial cells were detected in all
patients before the start of therapy, with pretherapy numbers
between 600 and 273,150 cells/ml (mean 11,876 cells/ml).
Duplicate analyses differed by less than 10%. Typical longitu-
dinal analyses (normalized to pretherapy values, which were
set at 100%) during the three epirubicin cycles are shown for
14 patients in Fig. 2a. The decrease in the number of circulat-
ing tumour cells (CTCs) from different breast cancer patients
varied, and the difference was up to several hundred-fold, indi-
cating that cells from individual patients respond differently to
the same therapy schedule. The same was true for the 16
patients treated with the epirubicin/cyclophosphamid sched-
ule (not shown).
Reductions in cell numbers (the nadir of circulating cell num-
bers was used) were strongly correlated (R2 = 0.97) with final
tumour reduction in the patients receiving dose-intensified epi-
rubicin (calculated as the difference between pretherapy vol-
ume (determined using magnetic resonance) and remaining
tumour volume at surgery (determined by the pathologist); 8/
14 patients underwent surgery; Fig. 2b and Table 1).
The epirubicin/cyclophosphamide group was further divided
into patients who did not receive subsequent herceptin ther-
apy (7/8 underwent surgery) and HER2/neu-positive patients
who received herceptin treatment after chemotherapy (6/8
underwent surgery; Table 1). The correlation coefficients
between CTC reduction with initial chemotherapy and tumour
volume reduction was R2 = 0.79 in the chemotherapy-only
group and R2 = 0.059 in the group in which chemotherapy
was followed by herceptin treatment. It should be noted that
measurements were performed during epirubicin/cyclophos-
phamide cycles only; this is because later analyses may be
perturbed by release of cells from decaying tumour tissue and
therefore were not included. Thus, although the circulating epi-
thelial cells in the HER2/neu-positive group did not respond
adequately to epirubicin/cyclophosphamide, tumours fre-
quently exhibited a good response at the end of therapy after
application of herceptin. The lack of correlation in the hercep-
tin treatment group indicates that subsequent antibody treat-
ment contributes to tumour reduction in a different manner,
which is not reflected in the initial response of CTCs to
chemotherapy.
Discussion
In patients with breast cancer we found that the first few
courses of neoadjuvant chemotherapy had identical influence
Figure 2
Changes in circulating tumour cell numbers Changes in circulating tumour cell numbers. (a) Fourteen typical courses of changes in cell numbers in breast cancer patients monitored during neo-
adjuvant (primary) therapy. (b) Comparison of the response of circulating tumour cells during the first three (or four) therapy cycles versus tumour 
reduction in the therapy regimen without herceptin (thick lines) and the regimen including herceptin (thin line).Breast Cancer Research    Vol 7 No 6    Pachmann et al.
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on CTC numbers, and that therapy reduced CTCs in the same
way as it affected the tumour per se. Because circulating epi-
thelial cells detected using our approach respond to chemo-
therapy in the same way as the tumour does, it is likely that
these cells in peripheral blood of untreated breast cancer
patients stem from the tumour. Also, the strong correlation
between the reduction in CTCs with chemotherapy and the
final reduction in size of the tumour indicates that monitoring
of CTCs, even during the first cycles of therapy, predicts
whether the tumour ultimately will respond adequately to this
therapy [13] (the course of which lasts almost half a year).
Unnecessary toxicity during neoadjuvant therapy could there-
fore be avoided by discontinuing ineffective therapy.
In contrast, in the HER2/neu-positive group circulating epithe-
lial cells did not respond adequately to chemotherapy, but a
large proportion of the tumours in ultimately exhibited com-
plete response to the entire therapy (including chemotherapy
and antibody therapy). This is in good agreement with the
known reduced responsiveness of HER2/neu-positive tumour
cells to chemotherapy (other than with subsequent antibody
therapy [14], during which analyses were not performed).
Table 1
Correlation between reduction in tumour size and reduction in circulating tumour cells with treatment
Patient group Tumour size before treatment 
(mm)
Tumour size at surgery (mm) Fold reduction in circulating cell 
numbers
Patients receiving dose-dense 
epirubicin
25 × 25 × 25 12 × 12 × 12 9.09
25 × 20 × 25 9 × 12 × 8 + small remnant 
tumour structures
14.70
70 × 50 × 25 70 × 50 × 20 1.00
85 × 85 × 85 38 × 26 × 22 666.67
50 × 50 × 50 0 111.11
60 × 60 × 60 ND 16.00
35 × 35 × 20 11 × 11 × 11 31.00
25 × 25 × 25 20 × 20 × 20 3.80
Patients receving epirubicin/
cyclophosphamide without 
herceptin
22 × 15 × 28 13 × 10 × 8 3.70
50 × 50 × 50 15 × 10 × 12 50.00
25 × 25 × 25 + DCIS 7 × 7 × 7 + small remnant tumour 
structures
18.18
40 × 30 × 30 27 × 27 × 27 3.68
36 × 40 × 26 15 × 15 46.00
50 × 30 25 × 35 × 17 0.80
15 × 11 × 13 and 8 × 9 × 8 17 × 15 × 9 23.00
Patients receiving epirubicin/
cyclophosphamide with 
herceptin
80 × 70 × 70 Not yet available
50 × 30 × 40 0 1.40
20 × 32 × 20 5 × 5 × 5 0.53
38 × 26 × 37 Right: 26 × 17; left: 17 × 13 and 
16 × 9 and 7 × 6 and 3 × 5
37.60
20 × 24 × 20 0 9.20
32 × 18 × 20 0 0.50
20 × 15 × 20 0 71.67
Tumour size (as determined using magnetic resonance) before initiation of treatment and tumour size at surgery (as determined by the pathologist) 
and reduction in circulating epithelial cells. Patients received dose-dense epirubicin (three cycles), epirubicin/cyclophosphamide (four cycles) 
without subsequent herceptin treatment, or epirubicin/cyclophosphamide (four cycles) and subsequent herceptin. DCIS, ductal carcinoma in situ; 
ND, not determined.Available online http://breast-cancer-research.com/content/7/6/R975
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Importantly, such analyses conducted during adjuvant
treatment, for which no other marker is yet available, could –
for the first time – help in determining immediately whether the
applied therapy is effective.
The significance of circulating epithelial cells in tumour
patients is still unclear. It is not known how long such cells sur-
vive [2] or to what extent they are able to form metastases. It
appears that the potential to grow into metastases may be
restricted to a small fraction [15] of 'stem cells' [16]. There-
fore, it may not be the simple number of CTCs but rather their
behaviour (decrease or increase) during the course of disease
that may predict patient outcome.
Conclusion
The method presented here permits easy, rapid, reliable and
reproducible repeated quantification of epithelial cells in
peripheral blood, and could serve as a tool for real-time moni-
toring of therapy in vivo. This will become especially valuable
in the adjuvant setting, where therapy has until now been given
without any ability to measure the efficacy of treatment.
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